| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/10/2001 | WO2001032874A2 Polypeptides and nucleic acids encoding same |
| 05/10/2001 | WO2001032872A2 Twik potassium channel molecules and uses therefor |
| 05/10/2001 | WO2001032867A1 Polypeptides with expanded primary signalling motifs |
| 05/10/2001 | WO2001032866A2 Hybrid adaptor receptors |
| 05/10/2001 | WO2001032865A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | WO2001032863A1 A novel polypeptide, a human apoptosis associated protein 12 and the polynucleotide encoding the polypeptide |
| 05/10/2001 | WO2001032862A1 A novel polypeptide, a human s4 ribosome protein 20 and the polynucleotide encoding the polypeptide |
| 05/10/2001 | WO2001032861A1 Tumour suppressor genes from chromosome 16 |
| 05/10/2001 | WO2001032859A1 Novel tumor suppressor gene |
| 05/10/2001 | WO2001032851A2 Modular transport systems for molecular substances and production and use thereof |
| 05/10/2001 | WO2001032846A1 Catalytic nucleic acid sequences |
| 05/10/2001 | WO2001032843A2 Enhanced immune recognition of pathogenic cells by icsbp expression |
| 05/10/2001 | WO2001032841A2 Method of in vitro t cell differentiation of cd34+ progenitor cells |
| 05/10/2001 | WO2001032837A1 19 human secreted proteins |
| 05/10/2001 | WO2001032836A1 Lactobacillus helvetius producing antihypertensive di- and tripeptides |
| 05/10/2001 | WO2001032832A2 Antisense inhibition of nucleolin expression |
| 05/10/2001 | WO2001032714A1 Recombinant fusion molecules |
| 05/10/2001 | WO2001032711A2 Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof |
| 05/10/2001 | WO2001032709A2 Polypeptides with non-natural primary signalling motifs |
| 05/10/2001 | WO2001032708A1 Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis |
| 05/10/2001 | WO2001032705A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | WO2001032704A1 Choline transporter like (ctl) membrane proteins involved in choline transport |
| 05/10/2001 | WO2001032703A1 Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies |
| 05/10/2001 | WO2001032701A1 A new polypeptide - subunit 15 of human f1f0 atp synthase and a polynucleotide encoding the same |
| 05/10/2001 | WO2001032699A1 Novel human udp-glucose: glycoprotein glucosyltransferase and a polynucleotide encoding the same |
| 05/10/2001 | WO2001032697A2 Virulence genes and proteins from brucella melitensis, and their use |
| 05/10/2001 | WO2001032696A2 Traf family proteins |
| 05/10/2001 | WO2001032695A2 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 05/10/2001 | WO2001032693A2 Trp-protein-related mtr1 protein and dna sequence coding therefor |
| 05/10/2001 | WO2001032691A1 Hcv ns3 protease inhibitors |
| 05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
| 05/10/2001 | WO2001032689A1 Salts of enalapril |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032676A1 25 human secreted proteins |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032674A1 26 human secreted proteins |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032596A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032223A1 Intravascular delivery of nucleic acid |
| 05/10/2001 | WO2001032222A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | WO2001032220A1 Gene therapy for diabetic ischemic disease |
| 05/10/2001 | WO2001032217A2 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 05/10/2001 | WO2001032213A1 Liver generation promoters and remedies for liver failure |
| 05/10/2001 | WO2001032204A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | WO2001032203A1 Protease inhibitors as modulators of periodontal wound healing |
| 05/10/2001 | WO2001032202A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | WO2001032201A2 A pharmaceutical composition having high cell membrane permeability |
| 05/10/2001 | WO2001032200A1 Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety |
| 05/10/2001 | WO2001032199A1 Secretin and secretin pharmaceuticals for treating lactose intolerance |
| 05/10/2001 | WO2001032198A1 Prevention and treatment of biomaterial-associated infections |
| 05/10/2001 | WO2001032197A2 Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders |
| 05/10/2001 | WO2001032196A1 Secretin fragments for treating autism |
| 05/10/2001 | WO2001032195A1 Dietary anti-adiposity food supplements and drugs based on thyrotropin-releasing hormone (trh) |
| 05/10/2001 | WO2001032194A1 Treatment of high cytokine secretion from macrophage cells |
| 05/10/2001 | WO2001032193A1 Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma |
| 05/10/2001 | WO2001032188A1 Compositions of orally administered nutritional supplements to repair articular cartilage |
| 05/10/2001 | WO2001032186A2 Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032153A2 Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032143A1 A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof |
| 05/10/2001 | WO2001032142A1 Cyclosporin formulation |
| 05/10/2001 | WO2001032137A1 Slimming composition containing a substance inducing il-6 production |
| 05/10/2001 | WO2001032133A2 Improved nit removal product |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032128A2 Human chemokine beta-13 |
| 05/10/2001 | WO2001032038A1 Fibrous-liponutritional complexes and compositions containing them |
| 05/10/2001 | WO2001032029A2 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 05/10/2001 | WO2001032022A1 YtgP |
| 05/10/2001 | WO2001032021A1 ytgp |
| 05/10/2001 | WO2001021804B1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/10/2001 | WO2001019379A3 Methods for treating muscular dystrophy with bone marrow cells |
| 05/10/2001 | WO2001016306A3 Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| 05/10/2001 | WO2001015719A3 Treatment of conjunctivitis |
| 05/10/2001 | WO2001007480A3 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 05/10/2001 | WO2001005974A3 The il-1l1 gene and polypeptide products |
| 05/10/2001 | WO2001003728A3 Gene therapy for enhancing and/or inducing angiogenesis |
| 05/10/2001 | WO2001001922A3 Use of substance p antagonists for the treatment of adenocarcinoma |
| 05/10/2001 | WO2000078327A3 Agents for treating malignant diseases using e1a-deficient adenoviruses with yb-1 protein-dependent replication |
| 05/10/2001 | WO2000077207A3 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto |
| 05/10/2001 | WO2000077035A3 Novel potassium channels and genes encoding these potassium channels |
| 05/10/2001 | WO2000072885A3 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 05/10/2001 | WO2000072865A3 Antifungal combination use |
| 05/10/2001 | WO2000072690A3 IMMOBILIZED LACTOFERRIN (Im-LF) ANTIMICROBIAL AGENTS AND USES THEREOF |
| 05/10/2001 | WO2000064488A3 Somatic transgene immunization and related methods |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO2000061170A3 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid) |
| 05/10/2001 | WO2000061067B1 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein |
| 05/10/2001 | WO2000016745A3 Micronised pharmaceutical compositions |
| 05/10/2001 | WO2000012711A8 Human membrane channel proteins |
| 05/10/2001 | US20010001066 Method for stimulating an immune response |
| 05/10/2001 | US20010001040 Alteration of macrophage-induced T cell suppression or concentration by the selective elimination or increase of tryptophan by administering an enzyme inhibitor of indole-amino 2,3-deoxygenase; viricides; abortion; fertility; |
| 05/10/2001 | US20010001039 Wound healing agents, especially for chronic wounds, e.g., diabetic wounds, ulcers, using keratinocytes grown on a transplantable solid support, e.g. collagen-coated beads; enclosure of mesh housing the support and placed in the wound |
| 05/10/2001 | DE19953696A1 Selective non-peptidic proteolytic enzyme analogue useful for the dissolution of plaques and treatment of polypeptide mediated illnesses comprises proteolytic amino acid residues bonded to a carrier molecule |
| 05/10/2001 | CA2390180A1 Choline transporter like (ctl) membrane proteins involved in choline transport |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389751A1 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | CA2389704A1 Compositions comprising edible oils and phytosterols and/or phytostanols substantially dissolved therein, method of making the same, and use thereof in treating or preventing cardiovascular disease, and its underlying conditions |
| 05/10/2001 | CA2389690A1 Selective toxin expression in angiogenic endothelial cells |